Christopher U. Jones
Expertise in
10
conditions

Dr. Christopher U. Jones

Radiation Oncology
2 Medical Plaza Drive, Suite 180, 
Roseville, CA 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
10
conditions
2 Medical Plaza Drive, Suite 180, 
Roseville, CA 

Overview

Christopher Jones is a Radiation Oncologist in Roseville, California. Dr. Jones is highly rated in 10 conditions, according to our data. His top areas of expertise are Familial Prostate Cancer, Lung Cancer, Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC). Dr. Jones is currently accepting new patients.

His clinical research consists of co-authoring 42 peer reviewed articles and participating in 25 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Rush Medical College Of Rush University

Residency

Harvard Medical School

Specialties

Radiation Oncology

Licenses

Diagnostic Radiology in CA

Board Certifications

Radiation Oncology - Board Certified

Hospital Affiliations

Sutter Roseville Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

2 Medical Plaza Care Center
2 Medical Plaza Drive, Suite 180, Roseville, CA 95661

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Carboplatin, Cisplatin, Pembrolizumab
Study Phase: Phase 2
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Radiation
Study Phase: Not Applicable
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: January 28, 2026
Intervention Type: Radiation, Drug
Study Drug: Sorafenib Tosylate
Study Phase: Phase 3
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Completed
Publish Date: January 14, 2026
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Suspended
Publish Date: January 14, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2/Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Radiation, Drug
Study Drugs: Enzalutamide, Bicalutamide, GnRH analog
Study Phase: Phase 2
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Radiation
Study Phase: Phase 3
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 20, 2025
Intervention Type: Procedure, Biological, Radiation
Study Drugs: Atezolizumab, Tocilizumab
Study Phase: Phase 2
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2024
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Lapatinib
Study Phase: Phase 2
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Enrollment Status: Completed
Publish Date: May 25, 2022
Intervention Type: Radiation
Study Phase: Phase 1
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: August 28, 2019
Intervention Type: Radiation
Study Phase: Phase 3
View 24 Less Clinical Trials

42 Total Publications

Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical Trials.
Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical Trials.
Journal: JAMA otolaryngology-- head & neck surgery
Published: December 04, 2025
Similar Doctors
Seth A. Rosenthal
Expertise in
2
conditions
Dr. Seth A. Rosenthal
Radiation Oncology
Expertise in
2
conditions
Dr. Seth A. Rosenthal
Radiation Oncology

2 Medical Plaza Care Center

2 Medical Plaza Drive, Suite 180, 
Roseville, CA 
 (0.1 miles away)
916-781-1225
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Seth Rosenthal is a Radiation Oncologist in Roseville, California. Dr. Rosenthal is highly rated in 2 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Breast Cancer, Metastatic Brain Tumor, and Prostatectomy. Dr. Rosenthal is currently accepting new patients.

Expertise in
31
conditions
Dr. Shyam S. Rao
Radiation Oncology
Expertise in
31
conditions
Dr. Shyam S. Rao
Radiation Oncology

Regents Of The Univ Of Ca

4501 X St, 
Sacramento, CA 
 (18.3 miles away)
916-734-5959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shyam Rao is a Radiation Oncologist in Sacramento, California. Dr. Rao is highly rated in 31 conditions, according to our data. His top areas of expertise are Tongue Cancer, Nasopharyngeal Carcinoma, Angiosarcoma of the Scalp, Bone Tumor, and Gastrostomy.

Anthony T. Pu
Expertise in
8
conditions
Dr. Anthony T. Pu
Radiation Oncology
Expertise in
8
conditions
Dr. Anthony T. Pu
Radiation Oncology

Sutter Medical Center | Anderson Lucchetti Women's & Children's Center

2825 Capitol Avenue, 
Sacramento, CA 
 (18.0 miles away)
916-454-6600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anthony Pu is a Radiation Oncologist in Sacramento, California. Dr. Pu is highly rated in 8 conditions, according to our data. His top areas of expertise are Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Breast Cancer, and Squamous Cell Lung Carcinoma. Dr. Pu is currently accepting new patients.

Frequently Asked Questions about Dr. Christopher U. Jones

How do I make an appointment with Dr. Christopher U. Jones?

You can book an appointment with Dr. Christopher U. Jones by calling their office at 916-781-1225. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Christopher U. Jones a top-rated expert for Familial Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Christopher U. Jones is classified as an Distinguished expert for Familial Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Christopher U. Jones specialize in?

While Dr. Christopher U. Jones is a Radiation Oncology, they have specific expertise in Familial Prostate Cancer, Lung Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Christopher U. Jones participate in research or clinical trials?

Yes. Dr. Christopher U. Jones has published 42 articles and abstracts on conditions like Familial Prostate Cancer. You can view a list of Dr. Christopher U. Jones's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Christopher U. Jones accept my insurance?

Dr. Christopher U. Jones accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 916-781-1225 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jones's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 47 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile